Pharmaceutical companies are exposing themselves to significant compliance, regulatory and supply chain risks by underestimating the impact of legal entity changes, according to a new report from international consulting firm BIP UK.

The report, Managing Legal Entity Changes in Global Pharma, reveals that what is often perceived as a routine administrative exercise can quickly become a complex global transformation programme. A single company name or legal entity change can trigger hundreds, and in some cases thousands, of regulatory actions across international markets, affecting product licences, GMP certificates, manufacturing authorisations, packaging artwork, quality systems and supply chain documentation.

As pharmaceutical organisations continue to evolve through mergers, acquisitions, restructures and operating model changes, legal entity updates are becoming increasingly common. However, many companies continue to underestimate the scale of activity required to implement these changes successfully across global regulatory, manufacturing and commercial operations.

According to the report, legal entity changes can affect product registrations, manufacturing and testing sites, regulatory dossiers and packaging components across more than 100 markets worldwide. The challenge is compounded by increasing regulatory scrutiny, interconnected global supply chains and a complex landscape of centralised, decentralised and national approval procedures, each with their own requirements and timelines.

Drawing on its experience supporting global pharmaceutical organisations, BIP UK has seen programmes involving more than 100 markets, multiple manufacturing and testing sites, and several thousand licence and SKU combinations. The firm's analysis found that legal entity changes frequently extend well beyond regulatory affairs teams, requiring coordinated action across quality, manufacturing, supply chain, packaging, artwork, commercial and programme management functions.

Without sufficient planning, organisations can face missed submission windows, approval delays, packaging rework, increased operational costs and, in some cases, risks to product supply continuity.

Ana Relva Pereira, Head of Portfolio, Programme and Project Management at BIP UK, comments: "Many organisations may view legal entity changes as administrative projects when, in reality, they can become enterprise-wide transformation programmes. A single change can create significant regulatory and operational complexity across global markets, which is why early planning, strong governance and cross-functional coordination are essential to maintaining compliance, protecting supply continuity, and identifying opportunities."

To minimise risk and maintain compliance, the report recommends that pharmaceutical organisations:

• Begin planning legal entity changes as early as possible to allow sufficient time for impact assessments and regulatory submissions.

• Conduct comprehensive global impact assessments covering licences, products, manufacturing and testing sites, GMP certificates, artwork, quality systems and supply chain documentation.

• Develop market-specific regulatory strategies that account for differing requirements across centralised, decentralised and national approval procedures.

• Align regulatory, manufacturing, supply chain and packaging timelines to avoid implementation gaps and reduce the risk of product supply disruption.

• Establish dedicated programme governance and cross-functional oversight to manage dependencies, risks and implementation milestones across global markets.

• Treat legal entity changes as enterprise-wide transformation programmes rather than standalone regulatory projects.

The report concludes that legal entity changes should be managed as strategic transformation programmes, not standalone regulatory projects, to help maintain compliance, minimise disruption and deliver change on time and within budget.

The full report, Managing Legal Entity Changes in Global Pharma, is available to download below.